We conducted two phase 1 trials of direct intratumoral injection of a recombinant E1E3-deleted adenovirus (AdR) encoding either the bacterial enzyme b-galactosidase (Ad.RSVbgal) or interleukin 2 (IL2, AdTG5327) into primary nonsmall-cell lung cancers of 21 patients. We report here virus shedding and the duration of virus expression in the tumor after intrabronchial injection of 10 7 , 10 8 or 10 9 PFU of adenovirus. The infectious AdR and the viral DNA were detected in PBL, plasma, stool and aerodigestive samples in a dose-dependent manner, since cell cultures and PCRs were found to be positive mainly for samples from patients who received the highest AdR dose (10 9 PFU). We detected b-galactosidase activity in the tumor biopsy samples of 66% of the patients, seemingly dose related, and only low levels of IL2 mRNA could be detected in tumor biopsy samples. E1 sequences were not detected by PCR in any of the PBL and bronchial samples collected after virus delivery, except in one patient. In this patient, E1 sequences were detected in PBL as well as in tumor biopsy samples collected at days 8, 30 and 60 and were correlated with longer b-galactosidase expression in tumor samples. PBL tested before and after virus delivery contained both E1 sequences indicating that they did not result from replication-competent adenovirus (RCA) E1 sequences present in the inoculum. In addition, only on the day of the injection was Ad.RSVbgal also detected in E1-positive PBL, indicating that virus replication in blood was very unlikely.
Introduction
Primary nonsmall-cell lung cancers (NSCLC) are highly malignant, fatal in most cases and the over-riding cause of cancer deaths in the Western world. 1 To date, the therapeutic options capable of improving the survival of NSCLC patients are limited. [2] [3] [4] [5] Advances in surgical techniques and in radiation and/or chemotherapy have permitted slightly longer survivals, but local failure and distant metastases are always a significant cause of morbidity and mortality. 6 Research has been particularly attentive to lung cancers as targets for gene therapy because of their prevalence, and the burning need for innovative therapies. Injecting vectors directly into an accessible endobronchial tumor by bronchoscopy represents a potentially novel anticancer therapeutic approach. Since recombinant adenoviruses are able to infect a wide variety of cells, they have been earmarked as vectors for gene transfer in many cancers including NSCLC. Nonreplicative adenoviruses are large doublestranded DNA viruses with tropism for lung cancer cells, and are associated with minor diseases in humans. 7 Producible with high titers in vitro, these adenoviruses are capable of transducing dividing and nondividing cells, an added advantage for their potential clinical utility. The level of transgene expression mainly depends on the strength and the cell type specificity of the promoter immediately upstream of the coding sequence of the foreign gene. The Rous Sarcoma Virus (RSV) long terminal repeat or the cytomegalovirus (CMV) promoter/enhancer are the most frequently used viral promoters because they are known to be the strongest and are able to express genes in a wide spectrum of tissues. Data currently available from several human trials have demonstrated that gene transfer to lung tumors is possible, and that the strategy aimed at overexpressing exogenous genes is potentially promising. Until now, adenovirus or retrovirus encoding the wild-type p53 gene were directly injected intratumorally in gene therapy clinical trials for lung cancer. In one of the first studies, a retrovirus vector containing the wild-type p53 gene, under the control of the b-actin promoter, was injected into lung cancers, and safety and transgene expression issues were addressed. 8 No clinically significant vector-related toxic effects were observed in this trial and retroviral sequences were not found in any of the nine different nontumorous tissues tested obtained from three autopsied patients. In other phase I clinical trials, adenovirus vectors containing wild-type p53 complementary DNA driven by the CMV promoter (Adp53) were injected into patients with advanced NSCLC. [9] [10] [11] [12] In one study, intratumoral injections of adenovirus had been complicated by short-lived systemic distribution and the likelihood of gene expression in other tissues. 9 The systemic passage of the vectors is dose-dependent and is facilitated by the fact that NSCLC are well-vascularized tumors. 13, 14 Furthermore, fever was observed as the most frequent treatment-related toxicity and may have been related in all cases to the systemic distribution of these vectors.
As the systemic circulation of adenovirus vectors and widespread transgene expression after intratumoral injection observed may raise safety concerns, we carefully analyzed virus shedding and the duration of virus expression in the tumor after intrabronchial injection of 10 7 , 10 8 and 10 9 PFU of Ad.RSVbgal or AdTG5327 containing, respectively, the Escherichia coli LacZ marker gene and human Interleukin-2 (IL2) complementary DNA.
Results

Clinical characteristics of patients
In total, 21 NSCLC patients (four females and 17 males) with a median age of 54 years (range, 40-70 years) were enrolled in the study (Table 1 ). All patients had unresectable lung cancers (stage IIIB or IV) and most of the patients had not previously been treated with conventional therapies. Two patients (patients 19 and 21) had previously been treated with chemotherapy and one with chemotherapy and radiotherapy (patient 15). The mean duration of isolation was 14 days (range, 11-21 days).
Vector biodistribution and dissemination
Throat swab, sputum and stool samples were collected and analyzed for the presence of wild-type adenovirus by culture onthe Hep2 cell line and PCR analysis, 4 days prior to injection of the recombinant adenovirus. During these two trials, 83 (39 PCR and 44 CPE) preinjection stool, throat swab and sputum samples were processed using this bioassay. The detection of wild-type adenovirus DNA was assessed by a nonserotype-specific hexon PCR, which could detect on ethidium gels, dilutions of a known concentration of purified Ad5 DNA as low as 100 ag, which is equivalent to 2.5 copies of wild-type DNA. In our study, one patient was found to be carrying wild-type DNA adenovirus, detected by PCR in throat swab and sputum samples and was therefore excluded from the protocol. None of the other patients were found to be carrying wild-type adenovirus by either technique. PCR analyses using primers specific for both transgenes were used to detect the presence of vector sequences in biological samples and infectious particles were detected by culture on the 293 cell lines and are shown, respectively, in Tables 2 and 3. As shown (Table 2 ), viral DNA was detected by PCR in several different samples from each patient. The transgene was detected by PCR in peripheral blood leukocyte (PBL) specimens collected immediately after AdR injection in all patients having received 10 8 and 10 9 PFU of adenovirus and in 1/6 patients after injection of 10 7 PFU. Among nine patients having received 10 9 PFU of AdR, 4 (44%) exhibited vector sequences in their PBL, 2 days after the viral injection. PBL from two patients (22%) were still positive at day 4 postinjection. The vector was present in plasma within 5 min of AdTG5327 injection in 8/9 patients tested. Plasma remained positive by PCR in three patients up to 2, 4 or 7 days. Plasma viral DNA was detected up to 7 days postinjection in patient 14, whereas PBL were always negative by PCR.
Infectious adenoviruses were detected on 293 cells in PBL and plasma in a dose-dependent manner, since cell cultures were positive for only the highest dose of 10 9 PFU of AdR. Virus cultures of BAL specimens collected within 5 min of virus injection were consistently positive in all patients. Only two sputum specimens from patients 9 and 10 were positive by cell culture: all other aerodigestive secretions were negative. In contrast to the cell culture results, recombinant virus DNA was detected by PCR in several different aerodigestive specimens from all patients. Most BAL samples were positive at PCR analysis during the 8 days after injection of AdTG5327, they remained positive at day 15 and 1 month after virus delivery, respectively, in seven and in three patients, having received 10 9 PFU. After injection of Ad.RSVbgal, BAL samples from nine (75%), five (45%) and four (50%) patients were positive within 30, 60 and 90 days, respectively. In nine patients who received 10 9 PFU of AdR, recombinant vector DNA was detected by PCR mainly in the sputum and more rarely in throat swabs. Sputum samples from patient 9 were still positive at day 60 after Ad.RSVbgal injection. Results from CPE assays indicated that AdTG5327 was excreted in stool specimens in three patients, 48 or 96 h after the injection of 10 9 PFU of AdTG5327. To corroborate these findings we also used an ELISA assay to detect IL2 protein. IL2 was detected in the supernatant of the CPE test on 293 cells from patient 21 at 3927175 pg/ml at day 2. Recombinant viral DNA was also detected by PCR in the stools of four patients, 2 or 4 days after injection.
Efficiency of gene transfer
We quantified IL2 mRNA expression and the percentage of positive b-gal tumor cells in tumor biopsy samples from, respectively, 9 and 12 patients. After injection of AdTG5327, tumor biopsy samples at days 8 and 15 were obtained from all patients and from 7/9 patients at day 30. Both native and total (native and recombinant) IL-2 mRNA were measured using a highly sensitive quantitative RT-PCR at days 8, 15 and 30. An internal standard was coamplified to saturation with the cDNA derived from the mRNA of interest for this purpose. The internal standards do not differ from the sequences of interest, except for a four-base deletion. 15 PCR efficiency on both sample and standard cDNA was ensured by the standards because the primers hybridize at a distance from the modified region. To control the yield of RNA extraction and cDNA synthesis from one sample to another, we also normalized all other mRNA measurements to a fixed amount (10 6 copies) of the actin transcript in the same sample (assuming that actin is expressed to a similar extent in the various samples). Oligonucleotides specific for IL2 were used for this study (see the Materials and methods section).
As shown in Table 4 , slight (r100) or undetectable expression of rIL2 mRNA (both native and total) was observed in all tumor biopsy samples from the six patients having received 10 7 and 10 8 PFU of AdTG5327. Detectable expression (E1000 copies) of total IL2 mRNA Virus shedding after intratumoral gene transfer F. Griscelli et al Characteristics include the diagnosis, disease stage according to the Eastern Cooperative Oncology Group staging system, the injected dose of adenovirus in plaque-forming units (pfu), previous treatment and the duration of TL2 isolation according to procedures recommended by the commission on Genetic Engineering
Virus shedding after intratumoral gene transfer In all, 12 patients received a single intratumoral injection of Ad.RSVbgal concomitant with chemotherapy. A biopsy before treatment was performed in all patients. In patient 9, a paraffin-embedded section showed an infiltration of the bronchial stroma by an epidermoid carcinoma (Figure 1b) . After virus delivery, tumor biopsies were analyzed in all patients, at days 8, 30 and 60, and in 9/12 patients at day 90. As shown in Table 4 , b-gal expression was observed in seven patients on day-8 frozen biopsy specimens: b-gal expression was detected in 45-55% of the tumor cells from patient 10 ( Figure 1a ), in 5-10% of tumor cells from patients 7, 8 and 9 ( Figure 1c) , and in less than 5% of tumor cells from patients 3 and 6 and three biopsy samples from 3 patients were negative. At days 30, 60, and 90, tumor biopsy samples were either negative or exhibited weak b-gal expression (less than 5% of blue-stained cells), except for samples from patient 9, which revealed 5 and 5-10% of blue-stained cells, respectively, at days 30 and 60 (Figure 
ND, not done; d, day after injection; À, absence of recombinant adenovirus.
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The day 60 samples from this patient were necrotic without identifiable tumor cells and only contained inflammatory cells (Figure 1d ). All biopsy samples (n¼145) were tested by specific PCR for detection of the transgene. After intratumoral injection of AdTG5327, 62, 75 and 100% of the specimens were positive at PCR analysis at day 8, after injection of 10 7 , 10 8 and 10 9 PFU of recombinant adenovirus, respectively. In the biopsy sample collected at day 15, vector DNA was detected in 88, 66 and 100% of samples tested, respectively, after injection of 10 7 , 10 8 and 10 9 PFU of AdTG5327. In biopsy specimens collected after 30 days, vector-derived DNA, although faint, was still present in 14 and 20% of the samples after injection of 10 7 and 10 8 PFU of AdTG5327, respectively, while 66% of the samples were positive after injection of 10 9 PFU of virus. After intratumoral injection of 10 9 PFU of Ad.RSVbgal at days 8, 30, 60 and 90, tumor biopsy samples were collected, respectively, from 20, 21, 20 and 16 different sites and analyzed by PCR. At day 8, after injection of Ad.RSVbgal, vector-derived DNA was found in 100% of the sites tested for 10 8 and 10 9 PFU and in 75% of sites tested for 10 7 PFU. After injection of 10 9 PFU of Ad.RSVb gal, vector-derived DNA was found in 53%, 46% and 36% of the specimens at days 30, 60 and 90, respectively. Amplification of the GAPDH gene by PCR was systematically performed on DNA extracts from biopsy samples to verify the integrity of the genomic DNA. Although most biopsy samples collected after Ad.RSVbgal and AdTG5327 delivery were positive at PCR analysis, the CPE assay on 293 and Hep2 cell lines were all negative except for specimens from patient 9, whose CPE tests on 293 cell lines were positive after injection of 10 9 PFU of Ad.RSVbgal at day 8, whereas culture on Hep2 cell lines from these samples were always negative.
Detection of RCA
All biological samples from this study were systematically tested on Hep2 cells for the detection of RCA. During the two clinical trials, 475 postinjection blood, sputum, throat swab, stool, urine and biopsy samples were processed using this bioassay and all were negative. The PCR technique was also used to detect E1 sequences and was able to identify as few as 2.5 copies of wild-type adenovirus genomes (Figure 2a, rows  1-3 ). RCA were tested by PCR on blood cells and bronchial samples from all patients at day 0 after injection of Ad.RSVbgal or AdTG5327. All samples tested after injection of AdTG5327 were negative for RCA, although transgene sequences could be detected. These results proved that E1 sequences were not present in lung and blood samples and that the risks of complementation of the adenoviral vector were minimal. All blood cell and bronchial samples tested after injection of Ad.RSVbgal were negative at E1 PCR analysis for 11/ 12 patients. Surprisingly, several blood and biopsy samples from patient 9 contained E1 sequences from the adenoviral genome. PCR products were analyzed by Southern blot using a probe recognizing the E1 sequence from both adenoviral serotypes 2 and 5. E1 sequences were detected by PCR in two different PBL specimens collected before and after Ad.RSVbgal injection ( Figure  2b, rows10-13) . PBL tested at days 2 and 4 also exhibited positive E1 sequences (Figure 2b , respectively, rows 15 and 17), whereas the two blood samples tested after day 8 were both negative (Figure 2b, rows 18 and 19) . From this patient, nine tumor biopsy samples were tested by PCR for the presence of E1 sequences. As shown in Figure 2b , two of the three tumor biopsy samples at day 8 were positive (rows 2 and 3), and one sample still remained positive at day 30 (row 4) and 60 (row 8). The Virus shedding after intratumoral gene transfer F. Griscelli et al two tumor biopsy specimens tested at day 90 no longer contained E1 sequences. All negative samples were tested for integrity of DNA by amplification of a house-keeping gene by qualitative PCR assay (data not shown).
Discussion
Adenovirus biodistribution and dissemination as well as the duration of virus expression in tumors were studied after intrabronchial injection of 10 7 , 10 8 and 10 9 PFU of Ad.RSVbgal or AdTG5327, expressing either b-galactosidase or IL2, respectively. A number of critical issues have been clarified by the results of these two phase 1 trials. First, the systemic circulation of vectors observed in these two trials after intratumoral injections may raise safety concerns. Vectors were detected in PBL by PCR, the day after injection in 16/21 patients tested (76%) and in plasma in 8/9 patients tested (88%). These results are consistent with those of a published trial in which an adenovirus expressing p53 was used. The authors noted that vectors administered via the same route were detected in plasma by PCR 30 min after injection in 16/ 18 patients tested (88%), and that DNA vectors were still detected in 13 patients (72%) 90 min after injection. 9 Consistent with the sensitivity limits of the CPE test (the 293 cell-based bioassay is capable of detecting as few as 100 PFU of AdR in plasma and PBL), infectious vectors were detected on 293 cells in blood samples from 4/9 patients (44%) in our two studies, only on the day on which 10 9 PFU of adenovirus were injected, suggesting that the detection of the vectors by cell culture is dependent on the doses injected. On the basis of our results, it appears that the adenovirus vectors used in the two trials can be safely delivered at 10 7 and 10 8 PFU. Only cultures of BAL samples collected immediately after injection were positive and no other samples contained live viruses. When a dose of 10 9 PFU was injected, only 2 and 3/21 patients had, respectively, positive sputum and stool samples 24-96 h after the injection ( Table 3) , indicating that these patients may spread recombinant adenovirus via natural secretions or stools. All throat swabs were negative at CPE assay. In the two trials, all PCR and cell culture analyses of urine samples were constantly negative. These last results are not consistent with those found in a previous trial, where all urine samples from patients (n¼24) having received 10 6 -10 11 PFU of Adp53 were found to be positive on 293 cells within 24 h of injection. 9 Secondly, neither patients nor staff were found to have wild-type adenoviruses in cultures of their biological samples throughout the two trials and none of the biological samples from hospital staff exhibited positivity for recombinant adenovirus. This signifies that there is no risk of crossinfection between patients and staff, at least in our experience. Finally, no adverse effect related to positive culture has been observed, thus consistent with the safety of this therapy.
In contrast to cell culture results, viral vectors were detected by PCR in several biological fluid specimens, both immediately after injection and over a prolonged follow-up period. Our PCR results for aerodigestive samples showed that all BAL were positive up to 90 days for 4/6 patients who received 10 8 or 10 9 PFU of Ad.RSVbgal and that sputum was positive in 71% of cases. Only one patient (patient 9) showed positivity in sputum samples up to day 60.
Another major point about this study is that gene transfer and expression were accomplished and demonstrated in a large number of patients over a long followup period, without obvious correlation with the level of antiadenoviral antibodies (data not shown). We detected, apparently, b-galactosidase activity in 8/12 patients (66%), in a dose-dependent manner. Higher transgene expression (5-10% to 55% of b-galactosidase-positive tumor cells) was confirmed in 83% of the patients treated with 10 9 PFU, whereas 50% of the patients who received lower doses showed only low transgene expression (o5% of b-galactosidase-positive tumor cells). In all patients, maximal adenovirus expression occurred 8 days after the injection and declined rapidly, since at day 30, b-galactosidase could not be detected except in two patients (patients 5 and 9). The dose-dependent effect observed here is consistent with that of other studies. Sterman et al 16 noted dose-related gene expression when mesothelioma patients were treated with intrapleural instillation of Ad-HSV-tk. Swisher et al 12 also showed that after intratumoral injection of Adp53 in NSCLC patients, p53 transgene expression could be demonstrated by RT-PCR in 56% of the patients treated with 10 9 PFU or more, whereas only 30% of the patients who received lower doses showed p53 transgene expression.
After the injection of AdTG5327, detectable expression of recombinant IL2 mRNA was observed in 2/3 tumor biopsy samples from patients having received 10 9 PFU of adenovirus. Only a low number of IL2 mRNA copies Figure 2 Southern blot analysis of E1-PCR products from PBL and tumor biopsy specimens from patient 9. PCR was performed using primers able to amplify a 197-bp fragment from the E1 region of the adenovirus. PCR products were submitted to Southern blot analysis using a 197-bp specific probe for the E1 region. (three independent samples were tested and are shown in lanes 1, 2 and 3), at day 30 (two independent samples were tested and are shown in lanes 4 and 5), at day 60 (two independent samples were tested and are shown in lanes 5 and 6) and at day 90 (two independent samples were tested and are shown in lanes 8 and 9). Southern blot analysis of E1-PCR products from PBL, collected in duplicate before injection (lanes 10 and 11) and 30 min after the injection (lanes 12 and 13), and collected at day 2 (lanes 14 and 15), 4 (lanes 16 and 17), and 8 (lanes 18 and 19).
Virus shedding after intratumoral gene transfer F. Griscelli et al (o1000 copies) could be detected, whereas none of the tumor biopsy specimens from patients treated with 10 7 or 10 8 PFU showed a significant increase in IL2 RNA. These results can be explained by the fact that the MLP promoter was used to drive the IL2 gene, instead of the RSV promoter, which was used to drive the LacZ gene. Indeed, the level of transgene expression mainly depends on the strength of the promoter immediately upstream of the coding sequence of the transgene. The strength of the MLP promoter is known to be lower than that of the RSV promoter and the CMV immediate-early promoter. Hence the reason why RSV and CMV, known to be strong promoters, are the most frequently used. 17 In our studies, a PCR assay was used to detect the E1 sequence, which generated a 197 bp fragment (nucleotides 1575-1772 from the adenovirus type 5 genome) corresponding to a region of the gene encoding for the E1B-19k protein of human adenovirus 5. The sensitivity of the PCR was 0.1-1 fg of viral DNA per reaction corresponding to 2.5-25 copies of E1-adenovirus sequences. All PBL and bronchial samples were tested on the day of the injection in order to detect RCA. All samples from 20 patients were negative at E1-PCR analysis, indicating that E1 sequences were not present in the lung and blood samples and that the potential for complementation of the adenovirus vector is minimal. In one patient (patient 9), several PBL and tumor biopsy samples tested were found to be positive at E1-PCR and Southern blot analysis using a probe specific for the E1 sequence from adenovirus types 2 and 5. PBL samples tested before the injection were also found to be positive, demonstrating that the E1 sequences detected were not the result of RCA E1 sequences present in the inoculum. PBL were positive up to day 4 and samples tested at day 8 were found to be negative. Thus, latent adenoviral genome was confirmed in the absence of infectious virus in this patient since all the CPE tests on Hep2 cells were found to be negative. Adenoviruses are known for latency in lymphoid tissues 18 and there are many molecular biological patterns of latent infections. The persistence of adenovirus in normal human hosts has been documented for 24 months after initial infection. 19, 20 The potential role of B and T lymphocytes in the maintenance of latency has been suggested by several groups of investigators who found low levels (40-70 genome copies per cell) of adenovirus DNA persisting in peripheral blood lymphocytes. 18 These last results could explain why only PBL were found to be positive at E1-PCR analysis and that this was never the case with other specimens such as aerodigestive secretions (sputum, swabs and BAL) and stools (data not shown). In the same patient, tumor biopsy samples were also found to be positive at E1-PCR analysis at day 8 in 2/3 sites and in 1/ 2 sites at day 30 and 60. On the other hand, the two sites at day 90 were found to be negative as well the Ad.RSVbgal DNA-PCR, indicating that all viral DNA had disappeared. Stable b-galactosidase expression (5-10%) was found in tumors up to 60 days, and infectious virus was found on 293 cell lines at day 8, suggesting that transcomplementation had occurred with the wild-type adenovirus genome present in tumors.
This study has documented virus shedding and transgene expression after injection of 10 7 -10 9 PFU of AdR. We have shown that up to 10 8 PFU of AdR can be safely administered, since infectious AdR were found exclusively in BAL collected just after the injection of the AdR. When a dose of 10 9 PFU was injected, two sputum samples and three stool samples contained infectious AdR over a short period of time. We demonstrated the presence of a latent adenovirus genome in PBL and tumors tissues in one patient. This finding correlated with the presence of infectious Ad.RSVbgal in tumor samples tested on 293 cell lines at day 8. Longer bgalactosidase expression was observed in tumors, since tumor biopsy samples continued to exhibit positivity at days 30 and 60. In contrast, only on the day of the injection could infectious Ad.RSVbgal and the lacZ gene be detected in E1-positive PBL, indicating that Ad.RSVb gal replication and wild-type adenovirus reactivation in blood were highly improbable.
Materials and methods
Recombinant adenovirus
The construction and generation of Ad.RSVbgal have previously been reported. 21, 22 Briefly, E1/E3-deleted replication-deficient recombinant adenovirus was constructed using a modified type 5 adenovirus genome. The RSV promoter was used to drive transcription of the LacZ gene. AdTG5327 is an E1/E3-deleted adenovirus derived from serotype 5, which expresses human IL-2 under the control of the Major Late Promoter (MLP) of the adenovirus. Both adenoviruses were propagated in the 293 permissive cell line. High titers of both adenovirus were supplied by Transgene SA (Strasbourg, France). The titers of the purified adenovirus were expressed in PFU. Total virus particles (pv) were also calculated and were considered to be 100 more higher than PFU. Thus, our conversion factor between PFU and pv was of 100.
Clinical protocol and patients
The protocol was an open-label, nonrandomized phase 1 escalation study designed to determine the duration of virus excretion in biological fluids and tumors after a single intratumoral injection of recombinant adenovirus by fiberoptic bronchoscopy. In this study, AdTG5327 or Ad.RSVbgal were administered at three dose levels (10 7 , 10 8 and 10 9 PFU, corresponding to 10 9 , 10 10 and 10 11 pv) in cohorts of three patients. A total of six patients received 10 9 PFU of Ad.RSVbgal. Patients with histologically proven NSCLC were enrolled in the trial. All patients had an unresectable advanced endobronchial tumor that was accessible by bronchoscopy with clinical evidence of bronchial obstruction. Patient clinical evaluation criteria have previously been described. 21 Written informed consent was obtained from all patients in accordance with French law governing biomedical research; this document stated that patients were aware of the investigational nature of this study. Patients were isolated according to procedures recommended by the Commission on Genetic Engineering. Two milliliter of Ad.RSVbgal or AdTG5327 vectors were administered directly into the tumor through the bronchoscope by means of Olympus NA1-C21-gauge needles. The virus suspension was divided into three aliquots and injected into three different areas in the tumor.
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Preparation of clinical samples for virus cultures and PCR analysis
Throat swab, sputum and stool samples were collected as previously described 23 and analyzed for the presence of wild-type adenovirus by culture and PCR analyses 4 days prior to virus injection. Blood samples (white blood cells and/or plasma) and bronchial aspirates were collected 5 or 30 min after the injection of AdTG5327 or Ad.RSVbgal, respectively, and then every 2 days. Throat swab, sputum, stool and urine samples were collected before injection (day 0) and every 2 days and processed as previously described, 23 until two successive negative results. Three tumor biopsy and bronchoalveolar lavage (BAL) fluid samples were collected at days 8, 30, 60 and 90 after the injection of Ad.RSVbgal and at days 8, 15 and 30 after the injection of AdTG5327. Specimens were processed, as previously described, 21 and 0.5 ml of treated samples were inoculated onto Hep2/293cells cells. DNA was extracted from all samples except for the tumor biopsy specimens using the QIAamp tissue Kit (Qiagen, Courtaboeuf, France). To extract DNA in biopsy samples, the tissues were processed, as previously described. 21 For controls, mock DNA extraction was undertaken at the same time as clinical samples and were likewise subjected to PCR amplification.
Detection of adenovirus by cell cultures
To detect both recombinant adenovirus and replicationcompetent adenovirus (RCA), biological samples were inoculated onto 293 cells (American Type Culture Collection CRL-1573, Rockville, MD, USA) permissive for culture of human Ad E1-deleted vectors or onto Hep2 cells (European Collection Animal Cell Culture-86030501, Wiltshire, UK), which are able to replicate non-E1-deficient human adenoviruses. Hep2 and 293 cell cultures were monitored daily over 10 days for the characteristic effect. On day 10, the culture medium was checked for the presence of adenovirus hexon using an enzyme immunoassay test (Dako SA, Trappes, France). Cultures without the adenovirus cytopathic effect or devoid of immunoreactivity were considered negative for the presence of adenovirus. In order to detect Ad.RSVbgal, samples were inoculated in three wells, two were used for the X-Gal test 24 performed 48 and 96 h after inoculation and one well was kept over 10 days to determine the adenovirus cytopathic effect.
PCR-based detection of AdTG5327, Ad.RSVbgal, RCA and genomic DNA PCR-based detection of AdTG5327 was based on targeting of a 343 bp sequence spanning the IL-2 portion of the IL-2 expression cassette and the SV40 polyadenylation signal (sense: 5 0 -CCAAGAAGGCCACAGAACT-GAAAC-3 0 and antisense: 5 0 -TTGTGAATTGTGATGC-TATTGC-3 0 ). PCR was conducted on 10 ml of template DNA with 0.5 mM of each primer, 0.06 mM of each of the dNTPs, 0.1 mg/ml of bovine serum albumin (BSA), 1.5 U Taq gold DNA polymerase (Perkin-Elmer Cetus, Courtaboeuf, France) in a total volume of 50 ml. PCR conditions were 941C (10 min); 38 cycles at 941C for 40 s, 601C for 25 s and 721C for 1 min, followed by a 5 min final extension at 721C. A nested PCR was used to detect the LacZ gene and amplification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was performed as previously described. 25 To test RCA, primers spanning the deleted Ad5E1 region were used (5 0 -AACGCCTTTGTTTGCTGAATGAGTT-3 0 and 5 0 -CTCTGTTCCAGCAAGTTACGCACAG-3 0 ), and PCR was conducted on 10 ml of DNA extract, with 0.1 mM of each primer, 4 ml of 2.5 mM of each of the dNTPs, 100 mg/ ml of BSA, 5 ml of 10 Â PCR buffer and 1.5 U Taq DNA Polymerase in a total volume of 50 ml. PCR conditions were 951C (10 min); 38 cycles at 941C for 30 s, 621C for 25 s and 721C for 45 s, followed by a 5 min final extension at 721C. Hexon adenovirus PCR was done, as previously described. 26 
Southern blot analysis
Five micrograms of E1-PCR products were run in a 2.5% agarose gel and transferred onto Hybond N membranes (Amersham, Arlington Heights, IL, USA). The blot was prehybridized for 1 h in 10 ml of solution containing 5 Â SSC, 0.02% SDS, 1% blocking reagent and 0.1% N lauryl sarcosine. The probe specific for the E1 gene (5 0 -TAATCTTGGTTACATCGACCTCAT-3 0 ) was labeled with digoxigenin-ddUTP according to standard procedures (Dig Oligonucleotide 3 0 -Enf labeling kit; Roche Diagnostics, Mannheim, Germany). Hybridization was performed for 18 h under the same conditions with 20 ml of labeled probe. The blot was washed twice in 2 Â SSC-0.1% SDS and twice in 1 Â SSC-0.1% SDS and was then incubated with the blocking solution (Amersham, Arlington Heights, IL, USA) and with antidigoxigenin-AP fragment antibody (Roche Diagnostics, 1: 20.000) for 1 h, respectively, followed by three washes in 0.1 M maleic acid, 0.15 M NaCl, 0.2 M NaOH, 0.3% Tween 20. E1 detection was then carried out by chemiluminescence using the CDP Start kit (Roche Diagnostics). The exposure time of the autoradiogram was 1.5 h.
Interleukin-2 and b-galactosidase expression
By reverse-transcriptase PCR analysis, tumor cells were examined for amplification of native and total IL2 RNA. The primer pair used for amplification of native IL2 sequences was 5 0 -TAGAAGAAGAACTCAAACCTCTG and 3 0 -GTGAAACCATTTTAGAGCCCCT and the primer pair used for the amplification of total IL2 sequences (native plus recombinant) was 5 0 -TAGAAGAAGAACT-CAAACCTCTG and 3 0 -ATGGTTGCTGTCTCATCAGC. Tumor tissues were resuspended in 6 M guanidium thiocyanate buffer, and total RNA was then purified by CsCl gradient centrifugation. cDNA was prepared by a standard method using reverse transcriptase and an oligo-dT primer (Gibco BRL). To quantify the IL2 transcripts expressed in the tumor, a previously described method was used. 15 Briefly, a constant amount of cDNA corresponding to the reverse transcription of 50 ng of total RNA was mixed with 10 2 or 10 copies of the cytokine standard cDNA and then amplified to saturation (40 cycles) in a 15 ml final volume. Aliquots (2 ml) of amplified material were copied in a 1 cycle runoff reaction (10 ml) primed with 6-carboxyfluorescein (FAM) fluorescent-labeled oligonucleotide specific for the IL2 gene (native or native plus recombinant). Runoff products were then subjected to electrophoresis on an ABI sequencer (Applied Biosystems, Foster city, CA, USA). The software was devised to measure both the length and the area under each detected DNA peak. The ratio of the standard and Virus shedding after intratumoral gene transfer F. Griscelli et al wild-type cDNA peaks provides a measurement of the ratios of the two initial molecular species, from which the number of cDNA copies in the sample can be calculated. The concentration of cDNA present in the original sample was obtained by determining the equivalent concentration of the internal standard. The following study results are expressed as the number of specific cytokine cDNA copies normalized to 10 6 copies of actin. IL2 was detected in the culture supernatant using a commercial Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA). The expression of b-galactosidase on frozen tumor sections by immunohistoenzymology was performed as described. 22 
